# US FDA approves Moderna’s first mRNA seasonal flu vaccine 2026-08-06T11:21:56+00:00 | Health & Science | Indian Opinion Desk Corroboration: 1 independent outlet The U.S. Food and Drug Administration has approved Moderna’s mFlusiva seasonal flu vaccine for adults aged 50 and older. It received traditional approval for people aged 50 to 64 and accelerated approval for those aged 65 and above. Moderna must conduct another study and submit further data for older adults. The decision followed a late-stage trial of more than 40,000 adults, in which the vaccine was 26.6% more effective than a standard-dose flu vaccine. Separate data showed stronger antibody responses than Sanofi’s high-dose vaccine among older adults. The shot is unlikely to generate major revenue before the second half of 2027. It uses mRNA technology, which could support quicker updates to match circulating flu strains. ## Coverage - thehindu.com Tags: influenza, Moderna, mRNA vaccine, public health, US FDA Canonical: https://indianopinion.org/us-fda-approves-modernas-first-mrna-seasonal-flu-vaccine/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/us-fda-approves-modernas-first-mrna-seasonal-flu-vaccine/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.